GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aldeyra Therapeutics Inc (STU:137) » Definitions » Float Percentage Of Total Shares Outstanding

Aldeyra Therapeutics (STU:137) Float Percentage Of Total Shares Outstanding : 83.05% (As of Jun. 04, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Aldeyra Therapeutics Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Aldeyra Therapeutics's float shares is 49.34 Mil. Aldeyra Therapeutics's total shares outstanding is 59.41 Mil. Aldeyra Therapeutics's float percentage of total shares outstanding is 83.05%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Aldeyra Therapeutics's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Aldeyra Therapeutics's Institutional Ownership is 24.47%.

Aldeyra Therapeutics Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Aldeyra Therapeutics's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=49.34/59.41
=83.05%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aldeyra Therapeutics (STU:137) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aldeyra Therapeutics Inc (STU:137) » Definitions » Float Percentage Of Total Shares Outstanding
Comparable Companies
RLMD HOWL MIRO NYMXF HRTX OCGN ADVM SGMO BDTX NKTR OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
ALDX:USA 137:Germany
Address
131 Hartwell Avenue, Suite 320, Lexington, MA, USA, 02421
Website
https://www.aldeyra.com
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. The company's product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer.

Aldeyra Therapeutics (STU:137) Headlines

No Headlines